SCHEMBL1750366

SCHEMBL1750366

CC(C)(C)[Si](OC1CCC2(CC1)CCN(Cc1c(Cl)cc(O)cc1Cl)C2=O)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.40
HDAC11 Q96DB2 1/20 0.35
RIPK1 Q13546 3/20 0.33
HCRTR2 O43614 9/20 0.33
HCRTR1 O43613 8/20 0.33
CTSB P07858 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32
S1PR5 Q9H228 2/20 0.32
TP53 P04637 1/20 0.32
MDM2 Q00987 1/20 0.32
PRMT1 Q99873 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750955 0.90 BACE1 (0.38) BACE1HCRTR2HCRTR1CTSBCTSS
SCHEMBL1750496 0.87 BACE1 (0.40) BACE1HDAC11RIPK1S1PR5
SCHEMBL1750080 0.87 BACE1 (0.41) BACE1HDAC11RIPK1HCRTR2HCRTR1
SCHEMBL1750766 0.86 BACE1 (0.37) BACE1HDAC11RIPK1HCRTR2HCRTR1
SCHEMBL1752202 0.85 BACE1 (0.39) BACE1HDAC11RIPK1HCRTR2HCRTR1
SCHEMBL2298905 0.81 BACE1 (0.33) BACE1S1PR5
SCHEMBL1751913 0.81 RIPK1 (0.39) BACE1RIPK1
SCHEMBL18208947 0.76 HSD11B1 (0.43) BACE1
SCHEMBL26098735 0.76 HCRTR2 (0.42) BACE1RIPK1HCRTR2HCRTR1CTSB
SCHEMBL18208394 0.74 BACE1 (0.45) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994176-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-08-09 US disclosed
US-7968585-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2011-06-28 US disclosed
EP-2035379-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-06-16 EP disclosed
EP-2021337-B1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2010-01-13 EP disclosed
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
US-20090099182-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-16 US disclosed
EP-2035379-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-03-18 EP disclosed
EP-2021337-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2009-02-11 EP disclosed
WO-2007127726-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed
WO-2007127763-A2 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099180-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 BACE1 155/4885HDAC11 107/4885RIPK1 2806/4885
US-20090099182-A1 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 BACE1 171/4885HDAC11 113/4885RIPK1 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.